Bremelanotide Results: What the Real Numbers Show in 2026

Bremelanotide at a glance:

• Drug class: Melanocortin receptor agonist
• Manufacturer: Palatin Technologies / AMAG Pharmaceuticals
• FDA approved: 2019
• Route: subcutaneous injection autoinjector
• Typical frequency: as needed before sexual activity
• Half-life: approximately 2.7 hours
• Cash price (US): $300-$1,000/month

The trial data on Bremelanotide is meaningful but easy to misread. We try to translate it into something useful for someone deciding whether to start, continue, or switch.

What the Trials Show

RECONNECT (Kingsberg 2019, Obstet Gynecol). Statistically significant improvement in HSDD desire and distress measures vs placebo.

The headline numbers matter, but so does the distribution. Trial averages obscure the fact that some people respond strongly and others minimally — that's true for essentially every drug in this class.

Realistic Expectations vs. Trial Numbers

Real-world results tend to underperform trial averages. Reasons:

• Trial participants are screened, monitored, and supported in ways most patients aren't
• Adherence to titration and lifestyle co-interventions is higher in trials
• Trials report mean change at a fixed endpoint; real life has interruptions, discontinuations, and slower titration

Plan around 70-80% of the trial benefit as a realistic personal expectation, and adjust based on how you respond in the first few months.

Timeline of Effects

For most users, the timeline looks like this:

• Weeks 1-4: dose titration; minimal therapeutic effect; side effects most prominent
• Weeks 4-12: appetite/glycemic effect becomes apparent; early weight loss for incretin agents
• Months 3-6: majority of weight loss accrues during this window for incretin therapies
• Months 6-12: continued slower progress; some plateau

We cover the timing question in more depth in Bremelanotide before and after.

Who Responds Best

The strongest predictors of good response across the GLP-1 class:

• Adherence to titration schedule
• Concurrent dietary changes (the medication makes them easier; it doesn't replace them)
• Sleep and stress management
• Realistic time horizon (12+ months, not 12 weeks)

For Bremelanotide, the same principles apply with class-specific nuances.

When Bremelanotide Isn't Working

If you're 12+ weeks in at the maintenance dose and seeing little benefit, options include:

• Reviewing adherence and timing
• Confirming dose escalation completed correctly
• Assessing for medical reasons that blunt response (medications, hypothyroidism, etc.)
• Switching to a different agent — see Flibanserin (Addyi) is the other FDA-approved HSDD medication

Long-Term Maintenance

For this compound, the long-term picture matters. Trial extension data and real-world cohorts show results depend heavily on continued use. Plan accordingly.

Bottom Line

If you're 6 months in at maintenance dose and seeing little benefit, it's worth a conversation about whether to switch agents or reassess the surrounding plan.

Frequently Asked Questions

Related Reading

• What Is Bremelanotide? Everything You Should Know Before Starting
• Bremelanotide Side Effects: 7 Things to Watch For (and How to Manage Them)
• Why Bremelanotide Costs So Much (and 5 Ways to Pay Less)
• Bremelanotide Cycle and Protocol: What Researchers Actually Use
• hCG: The Complete 2026 Guide (Mechanism, Dosing, Cost)
• What Is Oxytocin? Everything You Should Know Before Starting

Sources

• Kingsberg SA et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder. Obstet Gynecol 2019;134:899.
• Skorupskaite K et al. Kisspeptin and Reproduction in Humans. Hum Reprod Update 2014;20:485.

Individual results vary. This page summarizes published evidence and is not a guarantee of personal outcome.